FDA clears Ultragenyx GENGLYCOS gene therapy

Gene therapy vial in a lab symbolizing FDA clearance of new treatment for rare disorder GENGLYCOS

Key Points

01FDA grants accelerated approval to Ultragenyx (RARE)’s GENGLYCOS gene therapy
02Therapy targets glycogen storage disease type Ia in patients aged 8 and older
03Phase 3 GlucoGene trial showed reduced cornstarch needs vs placebo
04Ultragenyx (RARE) to run a 2‑year post‑marketing study and gained a review voucher

FDA accelerated approval for GENGLYCOS

The U.S. Food and Drug Administration has granted accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr), also referred to as DTX401. The therapy is approved to reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). This marks a regulatory milestone for a gene therapy intended for this rare metabolic disorder.

GENGLYCOS is described as a one-time gene therapy, positioning it as a treatment given in a single administration rather than recurrent dosing. The indication focuses specifically on lowering cornstarch requirements, which are part of the established nutritional management for people living with GSDIa.

Phase 3 GlucoGene trial underpinning approval

The FDA’s decision is supported by data from the Phase 3 GlucoGene trial, a 48-week randomized, double-blind, placebo-controlled study. The trial enrolled 46 participants aged eight years and older with GSDIa. In this study, patients treated with GENGLYCOS showed a statistically significant reduction in daily cornstarch requirements compared with those who received placebo, with a reported p-value of less than 0.001.

These results provided the primary clinical evidence for the accelerated approval pathway, demonstrating an effect on a key aspect of nutritional management. The trial design and duration offered comparative data over nearly one year of follow-up.

Post-approval commitments and monitoring

As a condition of accelerated approval, Ultragenyx (RARE) has agreed to conduct additional data collection after commercialization. The company will obtain two years of safety and efficacy data from 50 patients treated in the commercial setting and from 20 control patients. These patients will be followed through an enhanced GSDIa Disease Monitoring Program.

The control group in this post-marketing effort will consist of patients who are not eligible to receive GENGLYCOS due to anti-AAV8 antibodies. This structure is intended to provide comparative information while reflecting real-world treatment constraints for gene therapies that use AAV8 vectors.

Manufacturing, access, and financial impact

GENGLYCOS will be made available through a national network of Qualified Treatment Centers. These centers are characterized as having specialized expertise in administering gene therapies, which can involve complex handling and monitoring requirements. Ultragenyx plans to manufacture the product at its Gene Therapy Manufacturing Facility in Bedford, Massachusetts.

With the FDA approval of GENGLYCOS, Ultragenyx received a Priority Review Voucher, which can be used to obtain an expedited review for a future application. Market reaction to the news was positive, with one report indicating that Ultragenyx shares rose about 6.7% in after-hours trading to $28.48 following the announcement.

Key Takeaways

01GENGLYCOS becomes an FDA-cleared, one-time gene therapy option aimed at reducing cornstarch needs for GSDIa patients aged eight and older.
02The Phase 3 GlucoGene trial’s statistically significant reduction in cornstarch requirements was central to securing accelerated approval.
03Ongoing real‑world data collection from treated and control patients is a key requirement to confirm long‑term benefit and safety.
04Ultragenyx is integrating manufacturing and specialized treatment-center access while also gaining strategic value from a Priority Review Voucher.

References